Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptides rights issue 2024

Oncopeptides carries out a 300 million SEK rights issue

Find more information including questions and answers here.

Link to rights issue page, Oncopeptalks, Q&A for investors and recorded webcast

Oncopeptides presents new data at COMy Congress

New scientific data on melflufen has been accepted at the 10th annual World Congress on Controversies in Multiple Myeloma (COMy), held on May 23-26. The study focuses on the effectiveness of melflufen and shows promising results for the drug when treating patients with a particularly challenging form of multiple myeloma.

More information and Q&A for investors

Oncopeptides launches Spanish website.

Oncopeptides launches Spanish website

May 2, 2024 – As part of the company´s ongoing efforts to increase our visibility in Spain and strengthen relationships with the Spanish community, Oncopeptides recently launched www.oncopeptides.es.

Read more

Company news

Oncopeptides launches Spanish website.

Oncopeptides launches Spanish website

May 2, 2024

As part of the company´s ongoing efforts to increase our visibility in Spain and strengthen relationships with the Spanish community, Oncopeptides recently launched www.oncopeptides.es.

Read more

Clarification regarding recent decision from NICE

April 25, 2024

Oncopeptides has, as reported in the media, decided to not pursue an appraisal with the National Institute for Health And Care Excellence (NICE) in the United Kingdom at this time. On Thursday morning, the company clarified this decision in an interview with the news agency Direkt.

Read more

Oncopeptides secures national reimbursement for Pepaxti in Spain

April 15, 2024

Oncopeptides AB announces the approval of price and reimbursement allowing Oncopeptides to start commercializing its flagship drug Pepaxti in Spain as early as in 2024. Preparations ongoing with full launch expected to commence after summer.

Read more

Science news

Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress

May 16, 2024

Oncopeptides today announces that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Controversies in Multiple Myeloma (COMy), to be held on May 23-26.

Read more

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

March 1, 2024

Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.

Read more

Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

February 29, 2024

Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.

Read more

Investor news

MarketMakers-podd

Oncopeptides participates in the MarketMakers podcast

April 25, 2024

Oncopeptides' CEO Sofia Heigis recently participated in MarketMakers, one of Sweden's largest financial podcasts.

Read more
Oncopeptalks featuring Cristina Bando

Oncopeptalks featuring Cristina Bando, Spanish country manager

April 25, 2024

In this episode we meet with Cristina Bando, Spanish Country Manager at Oncopeptides for a short conversation on herself, the process of gaining market access in Spain and future of Pepaxti in Spain.

Read more
Sofia Heigis presenting at Oncology Forum

Sofia Heigis participated at Invest in Oncology Forum

April 11, 2024

Sofia Heigis recently presented Oncopeptides at the Invest in Oncology Forum, organized by Cord Communications. The presentation was followed by a Q&A session.

Read more
Picture Annual Report 2023

Released April 22, 2024

Oncopeptides publishes the 2023 Annual Report

Read report

Download

“Accelerating toward profitability”

CEO Sofia Heigis

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

Press release - May 16, 2024

Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress

Read press release
CEO Sofia Heigis - Oncopeptides AB

Released February 27, 2024

Oncopeptides publishes year-end report 2023

Read report

Download

“The fourth quarter sets the stage for revenue acceleration in 2024”

CEO Sofia Heigis

 

See the Webcast

Webcast presentation as pdf

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Q1 interim report 2024 will be published May 30, 2024

Upcoming events

2024-04-29 - 2024-05-29

Silent Period

Other

2024-05-30

Interim Report Q1 2024

Report

2024-05-31

Annual General Meeting 2024

Meeting

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Oncopeptides via e-mail